News | January 28, 2007

Abbott Vascular Takes Lead in PV Stent Market

Jan. 29, 2007 — Abbott Vascular surpassed Cordis for the first time in December 2006 as the market leader in peripheral stents in the U.S., according to Millennium Research Group's (MRG) Marketrack service.

Market share of peripheral stent units for Abbott Vascular jumped from 5 to nearly 30 percent between January and December 2006 following the gain of Guidant’s vascular product line, which Boston Scientific parceled off in its acquisition of Guidant last January. Abbott Vascular has realized increases in multiple product segments, including PV Stents, EPDs, PTA balloons and accessory devices.

New product availability is changing the peripheral vascular competitive landscape, MRG reports — Boston Scientific's NexStent, Cordis' Precise, and ev3's Protégé RX carotid stents were all approved in 2006. NexStent is still being launched and has yet to achieve significant market presence, but Precise is regaining market share initially lost to Abbott Vascular.

While, the NexStent is just now being launched and has yet to take significant share, the Precise is gaining market share every month. This stent may help Cordis regain some share lost to Abbott Vascular.

"This is the first month we have seen Abbott Vascular surpass Cordis as the market leader for stents," said Adrienne Lovink, senior analyst at MRG. "Abbott is now exhibiting the anticipated positive impact of the acquisition and has a combined share greater than the individual shares the companies held prior to the merger."

For more information about MRG visit www.MRG.net.

Related Content

First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral| April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral| March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
TOBA II BTK clinical trial, Intact Vascular, Tack Endovascular System, CLI, critical limb ischemia, first patient treated
News | Stents Peripheral| March 02, 2017
Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
Biotronik, Pulsar-18 bare metal self-expanding stent, BMS SE, BIOFLEX PEACE trial, 12-month results, VEITHsymposium 2016
News | Stents Peripheral| December 13, 2016
Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal self-expanding stent (...
LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral| December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
TCT 2016, TCT.16, main arena, late breaking trials
Feature | Cath Lab| September 28, 2016
September 28, 2016 — The Cardiovascular Research Foundation (CRF) included 11 late-breaking trials and 16 first repor
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
Overlay Init